HYFT
ImmunoPrecise Antibodies Ltd.
NASDAQ: HYFT · HEALTHCARE · BIOTECHNOLOGY
$1.19
+0.00% today
Updated 2026-04-30
Market cap
$54.19M
P/E ratio
—
P/S ratio
1.93x
EPS (TTM)
$-0.10
Dividend yield
—
52W range
$0 – $3
Volume
0.3M
ImmunoPrecise Antibodies Ltd. (HYFT) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-43.60%
Operating margin
-88.40%
ROE
-58.80%
ROA
-18.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-415365.00 | — | — | — |
| 2007 | — | $-415365.00 | — | — | — |
| 2008 | — | $-692989.00 | — | — | — |
| 2009 | — | $-478661.00 | — | — | — |
| 2010 | — | $-912033.00 | — | — | — |
| 2011 | — | $-5.14M | — | — | — |
| 2012 | — | $-283126.00 | — | — | — |
| 2013 | — | $-95609.00 | — | — | — |
| 2014 | — | $67988.00 | — | — | — |
| 2015 | $1.76M | $-62463.00 | -0.06% | -3.74% | -3.54% |
| 2016 | $1.90M | $-34494.00 | -0.04% | -1.82% | -1.82% |
| 2017 | $2.72M | $-5.57M | 27.33% | -51.00% | -204.67% |
| 2018 | $5.47M | $-5.20M | -23.63% | -87.79% | -95.03% |
| 2019 | $11.15M | $-7.77M | -16.92% | -56.99% | -69.72% |
| 2020 | $14.72M | $-5.18M | -3.92% | -29.13% | -35.19% |
| 2021 | $17.91M | $-7.34M | 63.67% | -21.87% | -40.98% |
| 2022 | $19.80M | $-17.09M | 46.32% | -86.49% | -86.29% |
| 2023 | $21.17M | $-27.21M | 34.59% | -138.16% | -128.53% |
| 2024 | $24.81M | $-26.43M | 37.05% | -57.48% | -106.51% |
| 2025 | $24.31M | $-29.97M | 47.31% | -50.47% | -123.30% |